Ann Surg Oncol

1. FAROOQ MS, Mattfeld V, Beniwal PC, Vargas GM, et al
   Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?
   Ann Surg Oncol. 2025 Sep 4. doi: 10.1245/s10434-025-18263.
   

   >> Share

   
   
2. PAPAI E, Ntoh K, Zhang L, Yu JQ, et al
   ASO Visual Abstract: The Utility of Preoperative PET/CT in Patients with Clinically High-Risk Melanoma.
   Ann Surg Oncol. 2025 Sep 3. doi: 10.1245/s10434-025-18266.
   

   >> Share

   
   
3. TAYLOR CD, Niba VS, Baskin AS, Mott NM, et al
   ASO Visual Abstract: Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.
   Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18254.
   

   >> Share

   
   

   
   Br J Cancer

4. VAN DAM S, Krijgsman D, Kucukkose E, Verdonschot MEL, et al
   Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.
   Br J Cancer. 2025 Sep 2. doi: 10.1038/s41416-025-03137.
   

   >> Share

   
   

   
   Br J Dermatol

5. HAFERKAMP S, Schilling B, Berking C, Drexler K, et al
   Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II study.
   Br J Dermatol. 2025 Sep 4:ljaf350. doi: 10.1093.
   

   >> Share

   
   
6. MISTRY K, Jeffrey P, Levell NJ, Kennedy O, et al
   A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21.
   Br J Dermatol. 2025 Sep 3:ljaf351. doi: 10.1093.
   

   >> Share

   
   

   
   Clin Cancer Res

7. VERGARA IA, Maher NG, Potter AJ, Paver EC, et al
   Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors.
   Clin Cancer Res. 2025;31:3742-3753.
   

   >> Share

   
   

   
   J Am Acad Dermatol

8. SHEN A, Arbesman M, Newell D, Chen J, et al
   Germline Pathogenic Variants (gPVs) and Immune-Related Adverse Events (IRAEs) in Patients with Melanoma Receiving Immune Checkpoint Inhibitors (ICI).
   J Am Acad Dermatol. 2025 Sep 2:S0190-9622(25)02743.
   

   >> Share

   
   

   
   Melanoma Res

9. CEREZUELA-FUENTES P, Aguado de la Rosa C, Crespo G, Berciano-Guerrero MA, et al
   Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.
   Melanoma Res. 2025 Sep 3. doi: 10.1097/CMR.0000000000001062.
   

   >> Share

   
   

   
   N Engl J Med

10. PASCH M, Tutein Nolthenius J
    Hutchinson's Sign in Subungual Melanoma In Situ.
    N Engl J Med. 2025;393:e13.
    

    >> Share

    
    

    
    Oncogene

11. BACCHIOCCHI A, Mak M, Khan ZM, Gong X, et al
    LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.
    Oncogene. 2025 Aug 30. doi: 10.1038/s41388-025-03538.
    

    >> Share

    
    

    
    Ophthalmol Retina

12. CARVALHO GM, Natividade MS, Jorge R
    Melphalan Followed by Brachytherapy for Uveal Melanoma.
    Ophthalmol Retina. 2025 Sep 3:S2468-6530(25)00363.
    

    >> Share

    
    
13. YI R, Steggall A, Binkley EM
    Fundus Depigmentation after Immunotherapy for Metastatic Uveal Melanoma.
    Ophthalmol Retina. 2025 Sep 3:S2468-6530(25)00361.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share